Related Experiment Video

Updated: Feb 21, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.4K

Atherosclerosis: analysis of the eNOS (T786C) gene polymorphism

A M Barbosa1,2, K S F Silva3, M H Lagares1,2

  • 1Departamento de Biologia, Núcleo de Pesquisas Replicon, , , Brasil.

Genetics and Molecular Research : GMR
|October 4, 2017
PubMed

Insights

This study investigated the T786C polymorphism in the eNOS gene and its association with coronary arteriosclerotic disease. The T allele showed a tendency towards association, but results were not statistically significant in the studied population.

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Molecular Biology

Background:

  • Coronary arteriosclerotic disease is a leading cause of mortality.
  • Atherosclerosis involves arterial narrowing and thrombosis, leading to severe clinical events.
  • Nitric oxide, regulated by the eNOS gene, plays a crucial role in vascular health.

Purpose of the Study:

  • To investigate the association between the T786C polymorphism of the eNOS gene and coronary arteriosclerotic disease.
  • To determine if specific genotypes (TT, TC, CC) correlate with the presence of atherosclerosis.
  • To analyze the influence of gender and smoking on this potential association.

Main Methods:

  • Genotyping of the T786C polymorphism in 297 patients with diagnosed atherosclerotic disease and controls.
  • Comparison of genotype frequencies between case and control groups using chi-square and G-tests.
  • Stratified analysis based on gender and smoking status.

Main Results:

  • The TC genotype was more prevalent in both groups, but without statistical significance.
  • No significant differences were observed in genotype distributions (TC/TT vs. CC) between cases and controls.
  • Gender and smoking status did not significantly alter the observed genotype associations.

Conclusions:

  • The T786C polymorphism of the eNOS gene did not show a statistically significant association with coronary arteriosclerotic disease in this cohort.
  • Despite a suggested tendency for the T allele, the study did not confirm a link between this polymorphism and atherosclerosis.
  • Further research with larger sample sizes may be needed to clarify the role of eNOS polymorphisms in cardiovascular disease.

More Related Videos

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

8.1K
An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations10:17

An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations

Published on: November 3, 2010

23.4K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
30
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
29
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
24
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
40
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.5K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
605